Immunopathology and treatments of Guillain-Barré syndrome and of chronic inflammatory demyelinating polyneuropathy;Mécanismes immunitaires et traitements du syndrome de Guillain-Barré et des polyradiculonévrites inflammatoires chroniques

Revue Neurologique

Volumn 158, Issue 3, 2002, Pages 301-310

  Radziwill, A J ^a   Kuntzer, T ^b   Steck, A J ^a  

^a Neurologische Universitatsklinik Basel   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BETA1A INTERFERON; CELL ADHESION MOLECULE; CYTOKINE; IMMUNOGLOBULIN; PREDNISONE; T LYMPHOCYTE RECEPTOR;

ANTIGEN PRESENTING CELL; CELLULAR IMMUNITY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DEMYELINATION; DRUG EFFECT; DRUG EFFICACY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MACROPHAGE ACTIVATION; MOLECULAR MIMICRY; MUSCLE WEAKNESS; NERVE CONDUCTION; NEUROMUSCULAR TRANSMISSION; PLASMAPHERESIS; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTIBODY SPECIFICITY; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CYTOKINES; DEMYELINATING DISEASES; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MODELS, IMMUNOLOGICAL; MOLECULAR MIMICRY; NEURAL CONDUCTION; PLASMA EXCHANGE; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; SYNAPTIC TRANSMISSION; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0036222597     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis
2. Criteria for diagnosis of Guillain-Barré syndrome
3. Assessment of current diagnostic criteria for Guillain-Barré syndrome
4. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria
5. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathies
6. Pre- and postsynaptic blockade of neuromuscular transmission by MillerFisher syndrome IgG at mouse motor nerve terminals
7. Neuromuscular blockade by IgG antibodies from patients with Guillain-Barre syndrome: A macro-patchclamp study
8. Serum anti-GQ-1b IgG antibody is associated with ophthalmoplegia in Miller-Fisher syndrome and Guillain-Barré syndrome: Clinical and immunohistochemical studies
9. Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases
10. Improvement following interferon beta in chronic inflamatory demyelinating polyradiculoneuropathy
11. Anti-tubulin autoantibodies in acquired demyelinating polyneuropathies
12. Report from an Ad Hoc Subcommitee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating (CIDP)
13. Treatment of Guillain-Barré syndrome with interferon-beta
14. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases
15. Advances in chronic inflammatory demyelinating polyneuropathy: Disease variants and inflammatory response mediators and modifiers
16. Interferon beta normalizes suppressor cell function in dysimmune neuropathies
17. Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy
18. Chronic inflammatory polyradiculoneuropathy
19. Prednisone-responsive hereditary motor and sensory neuropathy
20. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment
21. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy
22. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy
23. Atypical varieties of chronic inflammatory demyelinating neuropathies
24. Guillain-Barre syndrome variants in Emilia-Romagna, Italy, 1992-3: Incidence, clinical features, and prognosis
25. The spectrum of immune responses to campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders
26. Passive transfer studies in Guillain-Barré polyneuropathy
27. Severe axonal degeneration in acute Guillain-Barré syndrome: Evidence of two differences mechanisms?
28. Efficiency of plasma exchange in Guillain-Barré syndrome: Role of replacement fluids
29. Plasma exchange in Guillain-Barré syndrome: One-year follow-up
30. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders
31. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy
32. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon alpha-2a
33. Upper limb predominant, multifocal chronic inflammatory demyelinating polyneuropathy
34. Sur un syndrome de radiculonévrite avec hyperalbuminose du liquide cephalo-rachidien sans réaction cellulaire. Remarques sur les caracteres cliniques et graphiques des reflexes tendineux
35. Double-blind of intravenous methylprednisolone in Guillain-Barré syndrome
36. Electrophysiological classification of Guillain-Barré syndrome: Clinical associations and outcome
37. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy
38. Preceding infections, immune factors, and outcome in Guillain-Barre syndrome
39. Plasmaexchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study
40. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study
41. Demyelination induced by serum from patients with Guillain-Barré syndrome
42. Inflammatory mediators in demyelinating disorders of the CNS and PNS
43. Immunopathogenesis and treatment of the Guillain-Barre syndrome, part I
44. Immunopathogenesis and treatment of the Guillain-Barre syndrome, part II
45. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy
46. Nonneuralspecific T lymphocytes can orchestrate inflammatory peripheral neuropathy
47. Guillain-Barré syndrome
48. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome
49. Controlled trial of prednisolone in acute polyneuropathy
50. The concept and classification of Guillain-Barre syndrome and related disorders
51. Intravenous immunoglobulin for Guillain-Barré syndrome (Cochrane Review)
52. Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy
53. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
54. Distal acquired demyelinating symmetric neuropathy
55. Antigangliosid antibodies in Guillain-Barré syndrome after a recent cytomegalovirus infection
56. Transforming growth factor beta expression in reactive spinal cord microglia and meningeal inflammatory cells during experimental allergic neuritis
57. Transforming growth factor-beta 1 in experimental autoimmune neuritis-cellular localization and time course
58. Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome
59. The clinical correlates of high-titer IgG anti-GMw antibodies
60. Interferon beta1a in chronic inflammatory demyelinating polyneuropathy
61. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues
62. Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy
63. Multifocal demyelinating neuropathy with persistent conduction block
64. Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin A
65. TNF-alpha, INF-gamma and IL-2 mRNA expression in CIDP sural nerve biopsies
66. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases
67. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy
68. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy
69. Activitė démyélinisante sérique et syndrome de Guillain-Barré: Effet favorable des échanges plasmatiques
70. Elevated serum levels of endothelial leucocyte adhesion molecules in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy
71. Tumor necrosis factor alpha in peripheral nerve lesions
72. Motor neuropathy with multifocal conduction block
73. Chronic idiopathic polyneuropathy treated with azathioprine
74. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndome
75. Pathology of the Guillain-Barre syndrome
76. Long term follow up in chronic inflammatory demyelinating polyneuropathy (CIDP) under interferon beta-1a (IFN-b1a) and intravenous immunoglobulin (IVIg)
77. Plasma exchange for Guillain-Barré syndrome (Cochrane Review)
78. Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 Days versus 6 days
79. Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor
80. Focal lesions area feature of chronic inflammatory demyelinating polyneuropathy (CIDP)
81. The spectrum of chronic inflammatory demyelinating polyneuropathy
82. Experimental conduction block induced ba serum from a patient with anti-GM1 antibodies
83. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy
84. Le Syndrome de Guillain-Barré: Evolution des Idées
85. IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome
86. Neurological manifestations of malignant and non-malignant dysglobulinaemias
87. Appropriate number of plasma exchanges in Guillain-Barré syndrome
88. Plasmapheresis and acute Guillain-Barré syndrome
89. Eighty three years of the Guillain-Barré syndrome: Clinical and immunopathologic aspects, current and future treatments
90. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome
91. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: Immune mechanisms and update on current therapies
92. Diagnostic and classification criteria for the Guillain-Barre syndrome
93. High-dose intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, crossover study
94. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy
95. Treatment of patients with chronic inflammatory demyelinating polyneuropathy
96. Changes in referral pattern and its effect on outcome in patients with Guillain-Barre syndrome
97. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy
98. Prognostic factors of Guillain-Barre syndrome after intravenous immunoglobulin or plasma exchange
99. The interferons: Biological effects, mechanisms of action, and use in multiple sclerosis
100. Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma